Free Trial

Craneware (CRW) Competitors

Craneware logo
GBX 1,044 -18.00 (-1.69%)
As of 11:57 AM Eastern

CRW vs. EMIS, INS, KOO, RENX, and COG

Should you buy Craneware stock or one of its competitors? Craneware's main competitors and comparable companies include EMIS Group (EMIS), Instem (INS), Kooth (KOO), Renalytix (RENX), and Cambridge Cognition (COG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Craneware compare to EMIS Group?

Craneware (LON:CRW) and EMIS Group (LON:EMIS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Craneware pays an annual dividend of GBX 44.25 per share and has a dividend yield of 4.2%. EMIS Group pays an annual dividend of GBX 42 per share. Craneware pays out 79.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. EMIS Group pays out 8,936.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Craneware is clearly the better dividend stock, given its higher yield and lower payout ratio.

33.1% of Craneware shares are held by institutional investors. Comparatively, 105.6% of EMIS Group shares are held by institutional investors. 10.4% of Craneware shares are held by company insiders. Comparatively, 3.6% of EMIS Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

EMIS Group has a net margin of 17.23% compared to Craneware's net margin of 9.58%. EMIS Group's return on equity of 23.17% beat Craneware's return on equity.

Company Net Margins Return on Equity Return on Assets
Craneware9.58% 5.94% 2.28%
EMIS Group 17.23%23.17%7.99%

Craneware presently has a consensus price target of GBX 1,673.33, suggesting a potential upside of 58.76%. Given Craneware's stronger consensus rating and higher possible upside, equities analysts plainly believe Craneware is more favorable than EMIS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Craneware
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
EMIS Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

EMIS Group has lower revenue, but higher earnings than Craneware. EMIS Group is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Craneware£205.96M1.76£14.27M£56.0018.82
EMIS Group£176.86M0.00£30.48M£0.47N/A

Craneware has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, EMIS Group has a beta of -0.13, meaning that its stock price is 113% less volatile than the broader market.

In the previous week, Craneware's average media sentiment score of 0.00 equaled EMIS Group'saverage media sentiment score.

Company Overall Sentiment
Craneware Neutral
EMIS Group Neutral

Summary

Craneware beats EMIS Group on 9 of the 15 factors compared between the two stocks.

How does Craneware compare to Instem?

Craneware (LON:CRW) and Instem (LON:INS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Craneware currently has a consensus price target of GBX 1,673.33, indicating a potential upside of 58.76%. Given Craneware's stronger consensus rating and higher probable upside, equities research analysts clearly believe Craneware is more favorable than Instem.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Craneware
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Instem
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Craneware has a net margin of 9.58% compared to Instem's net margin of 5.50%. Instem's return on equity of 6.35% beat Craneware's return on equity.

Company Net Margins Return on Equity Return on Assets
Craneware9.58% 5.94% 2.28%
Instem 5.50%6.35%4.62%

Craneware has higher revenue and earnings than Instem. Instem is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Craneware£205.96M1.76£14.27M£56.0018.82
Instem£61.63M0.00£3.34M£0.14N/A

33.1% of Craneware shares are owned by institutional investors. Comparatively, 65.9% of Instem shares are owned by institutional investors. 10.4% of Craneware shares are owned by company insiders. Comparatively, 30.0% of Instem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Instem had 1 more articles in the media than Craneware. MarketBeat recorded 1 mentions for Instem and 0 mentions for Craneware. Craneware's average media sentiment score of 0.00 beat Instem's score of -0.55 indicating that Craneware is being referred to more favorably in the media.

Company Overall Sentiment
Craneware Neutral
Instem Negative

Craneware has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, Instem has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Summary

Craneware beats Instem on 8 of the 15 factors compared between the two stocks.

How does Craneware compare to Kooth?

Kooth (LON:KOO) and Craneware (LON:CRW) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Kooth currently has a consensus target price of GBX 345, indicating a potential upside of 87.50%. Craneware has a consensus target price of GBX 1,673.33, indicating a potential upside of 58.76%. Given Kooth's higher probable upside, analysts clearly believe Kooth is more favorable than Craneware.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kooth
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Craneware
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Craneware has a net margin of 9.58% compared to Kooth's net margin of 9.43%. Kooth's return on equity of 17.74% beat Craneware's return on equity.

Company Net Margins Return on Equity Return on Assets
Kooth9.43% 17.74% 10.12%
Craneware 9.58%5.94%2.28%

Craneware has higher revenue and earnings than Kooth. Kooth is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kooth£62.02M1.08£4.00M£15.0012.27
Craneware£205.96M1.76£14.27M£56.0018.82

In the previous week, Kooth's average media sentiment score of 0.00 equaled Craneware'saverage media sentiment score.

Company Overall Sentiment
Kooth Neutral
Craneware Neutral

Kooth has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market. Comparatively, Craneware has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

21.0% of Kooth shares are owned by institutional investors. Comparatively, 33.1% of Craneware shares are owned by institutional investors. 30.4% of Kooth shares are owned by insiders. Comparatively, 10.4% of Craneware shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Craneware beats Kooth on 8 of the 13 factors compared between the two stocks.

How does Craneware compare to Renalytix?

Craneware (LON:CRW) and Renalytix (LON:RENX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Craneware has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Craneware£205.96M1.76£14.27M£56.0018.82
Renalytix£3M12.15-£109.93M-£3.00N/A

33.1% of Craneware shares are owned by institutional investors. Comparatively, 14.0% of Renalytix shares are owned by institutional investors. 10.4% of Craneware shares are owned by insiders. Comparatively, 3.9% of Renalytix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Craneware currently has a consensus price target of GBX 1,673.33, suggesting a potential upside of 58.76%. Given Craneware's stronger consensus rating and higher possible upside, research analysts clearly believe Craneware is more favorable than Renalytix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Craneware
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Renalytix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Craneware has a net margin of 9.58% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Craneware's return on equity.

Company Net Margins Return on Equity Return on Assets
Craneware9.58% 5.94% 2.28%
Renalytix -506.25%675.00%-93.54%

In the previous week, Craneware's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.

Company Overall Sentiment
Craneware Neutral
Renalytix Neutral

Craneware has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Renalytix has a beta of 1.707, indicating that its share price is 71% more volatile than the broader market.

Summary

Craneware beats Renalytix on 11 of the 14 factors compared between the two stocks.

How does Craneware compare to Cambridge Cognition?

Craneware (LON:CRW) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Craneware has a net margin of 9.58% compared to Cambridge Cognition's net margin of -13.86%. Craneware's return on equity of 5.94% beat Cambridge Cognition's return on equity.

Company Net Margins Return on Equity Return on Assets
Craneware9.58% 5.94% 2.28%
Cambridge Cognition -13.86%-54.17%-0.30%

Craneware presently has a consensus price target of GBX 1,673.33, indicating a potential upside of 58.76%. Cambridge Cognition has a consensus price target of GBX 56, indicating a potential upside of 83.61%. Given Cambridge Cognition's higher possible upside, analysts clearly believe Cambridge Cognition is more favorable than Craneware.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Craneware
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cambridge Cognition
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Cambridge Cognition had 1 more articles in the media than Craneware. MarketBeat recorded 1 mentions for Cambridge Cognition and 0 mentions for Craneware. Cambridge Cognition's average media sentiment score of 0.38 beat Craneware's score of 0.00 indicating that Cambridge Cognition is being referred to more favorably in the news media.

Company Overall Sentiment
Craneware Neutral
Cambridge Cognition Neutral

Craneware has higher revenue and earnings than Cambridge Cognition. Cambridge Cognition is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Craneware£205.96M1.76£14.27M£56.0018.82
Cambridge Cognition£10.13M1.63-£1.58M-£3.10N/A

Craneware has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, meaning that its share price is 19% less volatile than the broader market.

33.1% of Craneware shares are held by institutional investors. Comparatively, 13.1% of Cambridge Cognition shares are held by institutional investors. 10.4% of Craneware shares are held by insiders. Comparatively, 3.3% of Cambridge Cognition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Craneware beats Cambridge Cognition on 11 of the 15 factors compared between the two stocks.

Get Craneware News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRW vs. The Competition

MetricCranewareHealthcare Technology IndustryHealthcare SectorLON Exchange
Market Cap£358.98M£1.98B£7.88B£2.84B
Dividend Yield3.02%3.89%2.47%5.11%
P/E Ratio18.6442.1433.3323.37
Price / Sales1.745.188.125.05
Price / Cash14.7215.7621.0220.23
Price / Book1.125.794.802.51
Net Income£14.27M-£19.09M£3.52B£5.88B
7 Day Performance3.57%-6.15%-4.56%-0.01%
1 Month Performance-4.57%-4.37%-2.78%-2.15%
1 Year Performance-49.37%-11.27%0.12%7.21%

Craneware Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRW
Craneware
N/AGBX 1,044
-1.7%
GBX 1,673.33
+60.3%
-48.9%£358.98M£205.96M18.64734
EMIS
EMIS Group
N/AN/AN/AN/A£1.23B£176.86M4,085.111,560
INS
Instem
N/AN/AN/AN/A£199.62M£61.63M5,928.57500
KOO
Kooth
N/AGBX 182.90
+0.0%
GBX 345
+88.6%
+41.5%£66.55M£62.02M12.19478
RENX
Renalytix
N/AGBX 5.25
-5.4%
N/A-20.5%£35.20M£3MN/A102

Related Companies and Tools


This page (LON:CRW) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners